S 444823Alternative Names: S-444823
Latest Information Update: 12 Nov 2016
At a glance
- Originator Shionogi
- Class Antipruritics; Skin disorder therapies
- Mechanism of Action Cannabinoid receptor agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Atopic dermatitis
Most Recent Events
- 01 Jan 2010 Phase-II clinical trials in Atopic dermatitis in Japan (Topical) (JapicCTI100996)